If you could give teenagers one piece of advice, what would it be?Janarbyek Avdikhadir
According to the World Health Organization, children aged 11-19 are considered adolescents. Up to 49% of Mongolia's population is between the ages of 11 and 25. That is why Mongolia is called the land of youth. Of these, 28% are children aged 11-19.
If you could give teenagers one piece of advice, what would it be?Janarbyek Avdikhadir
According to the World Health Organization, children aged 11-19 are considered adolescents. Up to 49% of Mongolia's population is between the ages of 11 and 25. That is why Mongolia is called the land of youth. Of these, 28% are children aged 11-19.
We watched it in mentoring term 1, if you dont remember it just have a quick look through it to get an idea... you dont have to read the whole thing again!
CON T EMPORARYP ED I AT R I C S . C O M A U G U S T 2 0.docxmccormicknadine86
CON T EMPORARYP ED I AT R I C S . C O M | A U G U S T 2 01724
PEER-REVIEWED FEATURE
Teen
Vaping
Dr Douglass is DNP program
director and assistant
clinical professor, DNP
Program and Nurse
Practitioner Programs,
Drexel University College
of Nursing and Health
Professions, Division of
Nursing, Graduate Nursing
Programs, Philadelphia,
Pennsylvania.
Dr Solecki is assistant
clinical professor of nursing,
DNP Program and Nurse
Practitioner Programs, Drexel
University College of Nursing
and Health Professions,
Division of Nursing,
Graduate Nursing Programs,
Philadelphia. The authors
have nothing to disclose in
regard to affiliations with
or financial interests in any
organizations that may have
an interest in any part of this
article.
The vaping culture of using non–cigarette
tobacco and electronic nicotine delivery
systems (ENDS) is the latest risky trend
among adolescents and young adults. Vap-
ing is the use of high-tech, advanced elec-
tronic devices such as electronic cigarettes
(e-cigarettes), refillable atomizers, and
other tobacco products as an alternative
or in addition to regular cigarettes.1 A con-
cerning 10-fold to 11-fold rapid rise noted
in middle and high school students poses
dangers of nicotine exposure to the pediat-
ric population.2
This article will explore the risk-taking
behavior of adolescents engaging in vaping;
the effects of vaping and the indiscriminate
use of nicotine products on the young; and
strategies that healthcare providers can use
to collaborate with patients and families to
reduce their risk of harm from this emerging
public health epidemic.
Background
The first e-cigarette was conceptualized
and patented in 1965 by Herbert Gilbert as
a safe and harmless modality to smoking
cigarettes.3,4 In 2003, an electronic atomiz-
er version was patented by Ruyan Technol-
ogy in China, marketed to the United States
in 2007, and touted as a healthier alternative
to smoking conventional cigarettes.3 Since
the emergence of Ruyan’s first-generation
e-cigarette, novel models have emerged in
design, engineering, and nicotine delivery
methods resulting in second-, third-, and
fourth-generation ENDS delivery devices.4
Modern generation devices have included
mid-sized e-cigarettes known as personal va-
porizers (PVs), which are similar to a pen or
laser pointer.4 The advanced personal vapor-
izers (APVs) contain a mechanical firing de-
vice called a “mod” (short for “modification”)
that may be used in conjunction with differ-
ent atomizers (tank systems), and they vary in
size, shape, and delivery methods. The most
innovative and advanced devices, however,
are regulated “vape mods,” which contain
an internal circuitry. Lingo used among the
diversity of delivery devices includes vapes,
vape pens, e-cigs, e-hookahs, mods, and tank
systems.3,4
Regardless of the novel delivery devices,
use ...
Primary Care Interventions for Prevention and Cessation of Tob.docxLacieKlineeb
Primary Care Interventions for Prevention and Cessation of Tobacco Use
in Children and Adolescents
US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force
Summary of Recommendations
The USPSTF recommends that primary care clinicians provide interventions, including education or
brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents. B
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and
harms of primary care–feasible interventions for the cessation of tobacco use among school-aged
children and adolescents.
I
See the Figure for a more detailed summary of the recommendation for clinicians. See the Practice Considerations section for more information on effective
interventions to prevent initiation of tobacco use and for suggestions for practice regarding the I statement. USPSTF indicates US Preventive Services Task Force.
IMPORTANCE Tobacco use is the leading cause of preventable death in the US. An estimated
annual 480 000 deaths are attributable to tobacco use in adults, including from secondhand
smoke. It is estimated that every day about 1600 youth aged 12 to 17 years smoke their first
cigarette and that about 5.6 million adolescents alive today will die prematurely from a
smoking-related illness. Although conventional cigarette use has gradually declined among
children in the US since the late 1990s, tobacco use via electronic cigarettes (e-cigarettes) is
quickly rising and is now more common among youth than cigarette smoking. e-Cigarette
products usually contain nicotine, which is addictive, raising concerns about e-cigarette use
and nicotine addiction in children. Exposure to nicotine during adolescence can harm the
developing brain, which may affect brain function and cognition, attention, and mood; thus,
minimizing nicotine exposure from any tobacco product in youth is important.
OBJECTIVE To update its 2013 recommendation, the USPSTF commissioned a review of the
evidence on the benefits and harms of primary care interventions for tobacco use prevention
and cessation in children and adolescents. The current systematic review newly included
e-cigarettes as a tobacco product.
POPULATION This recommendation applies to school-aged children and adolescents younger
than 18 years.
EVIDENCE ASSESSMENT The USPSTF concludes with moderate certainty that primary
care–feasible behavioral interventions, including education or brief counseling, to prevent
tobacco use in school-aged children and adolescents have a moderate net benefit. The
USPSTF concludes that there is insufficient evidence to determine the balance of benefits
and harms of primary care interventions for tobacco cessation among school-aged children
and adolescents who already smoke, because of a lack of adequately powered studies on
behavioral counseling interventions and a lack of studies on medications.
RECOMMENDATION The USPSTF recommends that.
We watched it in mentoring term 1, if you dont remember it just have a quick look through it to get an idea... you dont have to read the whole thing again!
CON T EMPORARYP ED I AT R I C S . C O M A U G U S T 2 0.docxmccormicknadine86
CON T EMPORARYP ED I AT R I C S . C O M | A U G U S T 2 01724
PEER-REVIEWED FEATURE
Teen
Vaping
Dr Douglass is DNP program
director and assistant
clinical professor, DNP
Program and Nurse
Practitioner Programs,
Drexel University College
of Nursing and Health
Professions, Division of
Nursing, Graduate Nursing
Programs, Philadelphia,
Pennsylvania.
Dr Solecki is assistant
clinical professor of nursing,
DNP Program and Nurse
Practitioner Programs, Drexel
University College of Nursing
and Health Professions,
Division of Nursing,
Graduate Nursing Programs,
Philadelphia. The authors
have nothing to disclose in
regard to affiliations with
or financial interests in any
organizations that may have
an interest in any part of this
article.
The vaping culture of using non–cigarette
tobacco and electronic nicotine delivery
systems (ENDS) is the latest risky trend
among adolescents and young adults. Vap-
ing is the use of high-tech, advanced elec-
tronic devices such as electronic cigarettes
(e-cigarettes), refillable atomizers, and
other tobacco products as an alternative
or in addition to regular cigarettes.1 A con-
cerning 10-fold to 11-fold rapid rise noted
in middle and high school students poses
dangers of nicotine exposure to the pediat-
ric population.2
This article will explore the risk-taking
behavior of adolescents engaging in vaping;
the effects of vaping and the indiscriminate
use of nicotine products on the young; and
strategies that healthcare providers can use
to collaborate with patients and families to
reduce their risk of harm from this emerging
public health epidemic.
Background
The first e-cigarette was conceptualized
and patented in 1965 by Herbert Gilbert as
a safe and harmless modality to smoking
cigarettes.3,4 In 2003, an electronic atomiz-
er version was patented by Ruyan Technol-
ogy in China, marketed to the United States
in 2007, and touted as a healthier alternative
to smoking conventional cigarettes.3 Since
the emergence of Ruyan’s first-generation
e-cigarette, novel models have emerged in
design, engineering, and nicotine delivery
methods resulting in second-, third-, and
fourth-generation ENDS delivery devices.4
Modern generation devices have included
mid-sized e-cigarettes known as personal va-
porizers (PVs), which are similar to a pen or
laser pointer.4 The advanced personal vapor-
izers (APVs) contain a mechanical firing de-
vice called a “mod” (short for “modification”)
that may be used in conjunction with differ-
ent atomizers (tank systems), and they vary in
size, shape, and delivery methods. The most
innovative and advanced devices, however,
are regulated “vape mods,” which contain
an internal circuitry. Lingo used among the
diversity of delivery devices includes vapes,
vape pens, e-cigs, e-hookahs, mods, and tank
systems.3,4
Regardless of the novel delivery devices,
use ...
Primary Care Interventions for Prevention and Cessation of Tob.docxLacieKlineeb
Primary Care Interventions for Prevention and Cessation of Tobacco Use
in Children and Adolescents
US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force
Summary of Recommendations
The USPSTF recommends that primary care clinicians provide interventions, including education or
brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents. B
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and
harms of primary care–feasible interventions for the cessation of tobacco use among school-aged
children and adolescents.
I
See the Figure for a more detailed summary of the recommendation for clinicians. See the Practice Considerations section for more information on effective
interventions to prevent initiation of tobacco use and for suggestions for practice regarding the I statement. USPSTF indicates US Preventive Services Task Force.
IMPORTANCE Tobacco use is the leading cause of preventable death in the US. An estimated
annual 480 000 deaths are attributable to tobacco use in adults, including from secondhand
smoke. It is estimated that every day about 1600 youth aged 12 to 17 years smoke their first
cigarette and that about 5.6 million adolescents alive today will die prematurely from a
smoking-related illness. Although conventional cigarette use has gradually declined among
children in the US since the late 1990s, tobacco use via electronic cigarettes (e-cigarettes) is
quickly rising and is now more common among youth than cigarette smoking. e-Cigarette
products usually contain nicotine, which is addictive, raising concerns about e-cigarette use
and nicotine addiction in children. Exposure to nicotine during adolescence can harm the
developing brain, which may affect brain function and cognition, attention, and mood; thus,
minimizing nicotine exposure from any tobacco product in youth is important.
OBJECTIVE To update its 2013 recommendation, the USPSTF commissioned a review of the
evidence on the benefits and harms of primary care interventions for tobacco use prevention
and cessation in children and adolescents. The current systematic review newly included
e-cigarettes as a tobacco product.
POPULATION This recommendation applies to school-aged children and adolescents younger
than 18 years.
EVIDENCE ASSESSMENT The USPSTF concludes with moderate certainty that primary
care–feasible behavioral interventions, including education or brief counseling, to prevent
tobacco use in school-aged children and adolescents have a moderate net benefit. The
USPSTF concludes that there is insufficient evidence to determine the balance of benefits
and harms of primary care interventions for tobacco cessation among school-aged children
and adolescents who already smoke, because of a lack of adequately powered studies on
behavioral counseling interventions and a lack of studies on medications.
RECOMMENDATION The USPSTF recommends that.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
3. Background
Public health concerns about children, young people and e-cigarettes:
‘Gateway’ effect?
Marketing
Channels previously used for traditional cigarettes
Plus celebrity endorsements, online promotions and social media
Growing number of e-cigarette product types, flavours and product innovations
Investment in e-cigarette point-of-sale displays
‘Renormalisation’ of smoking?
4. Previous review
Review published by Public Health England in May 2014
Identified 9 studies on use in children (up to March 2014).
One UK study
In the studies we reviewed, with the exception of one Polish survey, ever use was reported by fewer than one in ten children and was concentrated in young people who smoke
5. Update
Applied the same search strategy in October 2014 to identify all published peer-reviewed studies of young people and e- cigarettes
Also looked for ‘grey’ literature from the UK
We identified 23 new studies/surveys, of which 6 were grey literature (i.e. not been or unlikely to have been peer-reviewed)
32 studies/surveys in all
These are English language studies only.
6. Use in Great Britain
The only representative survey of young people in the UK (GB only) is the work conducted by YouGov for ASH in March 2013 and repeated in March 2014
In 2013, 67% of 11-18 year olds had heard of electronic cigarettes rising to 84% in 2014.
Of these, 5% had ever tried an e-cigarette in 2013 and 8% in 2014. Use was highly concentrated in current smokers.
7. Which ONE of the following is closest to describing your experience of e-cigarettes?
Source: ASH (2014) YouGov survey, Base: All children aged 11 to 18 (2,068). Fieldwork dates: 21st March to 1st April 2014
Don't want to say
I use them often (more than once a week)
I use them sometimes (more than once a month)
I have tried them once or twice
I have never used them
E-cigarette use by children in Great Britain
Not aware of e-cigarettes
8. Which comes first?
The GB survey asked children about e-cig vs tobacco cigarette initiation
Source: ASH (2014) YouGov survey, Base: All children aged 11 to 18 who had heard of e-cigarettes and tried them (n=157) Fieldwork dates: 21st March to 1st April 2014
I tried using an e-cigarette before I first tried smoking a real cigarette
I have never smoked a real cigarette
but have tried an e-cigarette
I don't remember
I tried smoking a real cigarette before I first tried
using an e-cigarette
9. What about other countries?
Data relating to ever use is available from 10 countries
Direct comparisons are very difficult with published data because of:
Differences in age range (youngest in surveys=11, oldest=19)
Differences in questions asked
Obtaining raw data from authors may allow for some comparisons
10. Ever and current use
In surveys conducted between 2011 and 2014, recorded ever use varied very significantly - from 5% to 62%
Amongst repeat cross sectional surveys there is a consistent pattern of rising use between years
Except in one Polish study, rates of regular use are much lower, commonly less than 10%.
Current use in never smokers also remains low (the highest identified rate is 2%).
11. Survey comparisons
Some surveys reporting much lower levels of use amongst never smokers were excluded
from this table
Source: Dutra, K and Glanz, S (2014) High international electronic cigarette use among never
smoker adolescents, Journal of Adolescent Health, 595-597
12. E-cigarette/smoking by children: USA
Source: US CDC data from National Youth Tobacco Survey 2011 and 2012. Graph from Bates & Rodu
13. Repeat cross-sectional survey in Poland
Source: Goniewicz, M et al (2014) Rise in electronic cigarette use amongst adolescents in Poland, Journal of Adolescent Health, 55, 713-715
14. What about the ‘gateway’
Until we have reliable longitudinal data on young people and e-cigarettes, theories about these products being a ‘gateway’ to smoking are just that – theories.
However we do need to recognise that a number of young people in a range of countries are exposed to nicotine for the first time by using an e-cigarette.
15. Flavours
Concerns about E-liquid flavours and youth appeal have been raised
A number of studies and consumer surveys have looked at flavour preferences in adult users.
As an example, a recent survey of 800 vapers in Germany, Austria and Switzerland asked about liquid flavour preferences.
Source: PowerCigs (2014) www/powercigs- shop.de. Online consumer survey October 2014.
16. Research Underway
Youth Tobacco Policy Survey (YTPS) funded by Cancer Research UK
Monitors youth response to tobacco marketing and tobacco control since 1999
2014, 7th wave
New e-cigarette questions
Survey is currently in the field
To develop questions we conducted 6 focus groups with 11-16 year olds in central Scotland (n=34) in April and May 2014 (ethics approval and parental consent obtained).
17. Findings
Initial discussions
E-cigarettes seen as a distinct product type but
Lack of terminology and language surrounding them
This poses problems for the survey
Knowledge often came from a
family member who had used
e-cigarettes to try to stop smoking
For adult smokers who
want to stop smoking
For situations where smoking prohibited
“at football games you’re not allowed to smoke real ones, you see people with the e-ones” (boy, 13-14)
“fake cigarettes”
“vapour stuff”
“electric type ones”
“adults” “parents” “people that smoke” “Nobody young does them”
18. Views on marketing
E-cigarette marketing
Some awareness of e-cig marketing but
Lack of engagement
Little brand awareness
Some. I’ve only heard it once or twice, erm, a little while ago, and it just says, like I think there’s one about nicotine as well (girl, 11-12)
Sometimes you get like adverts, is it SKYCIG or something like that? It’s like the fake cigarette, for er, people to stop smoking (girl, 11-12)
19. Sports Sponsorship
E-cigarette companies sponsoring sports events, have you come across that at all?
-No
-No
-Erm
-None
No, you haven’t come across that. Would you expect these companies to be sponsoring things like that?
-No, I wouldn’t expect it
-Not yet
-Not sporting events
-Because sport, like its not frowned upon but it’s like you don’t see an athlete that smokes
-I don’t know if they’re allowed to sponsor anyway (boys, 15-16)
20. Sports Sponsorship, cont.
-I have seen them a lot
-Yeah, they sponsor something
-I think they do
The SKYCIG?
-Yeah
-I think at the football you see them
-And the packets
OK, and you thought you’d seen that one before as well, can you remember where?
-I think I just seen it (sighs) I can’t remember, I think that’s one that’s always at the tills, I’m not sure though
21. Packaging and Flavours
Once exposed to different product/pack styles:
Younger participants surprised by the range of flavours
Some e-cigarettes shown did seem to increase appeal for participants:
Sweet and fruity flavours
Bright colours
‘Pen’-type devices
Rated by some as ‘fun’, ‘cool’, ‘stylish’, ‘for people who have never smoked’, ‘for someone like me’, ‘tempted to try’.
They might want to try it if they want to smoke….
like your friends smoke, you wouldn’t want to start (smoking) because they can be more addictive than these can be (girl, 11-12)
For fun or something… for somebody that’s kind of like starting but they don’t want to like get really addicted (boy, 11-12)
22. Who are e-cigarettes for?
None of them are meant for us are they? (laughing)
Not really
We’re not smokers
They’re not designed for us, they’re designed for people that need help to stop smoking
But then candyfloss might be for them (never smoker)
The candyfloss could be used by people…
The candyfloss and the chocolate one
They might be for people who have never smoked
For fun
They’d have a different taste
They might think it tastes good
Yeah, they might want to try cigarettes but don’t want to (smoke)
23. Findings
Imagery
Unlike previous work conducted with tobacco packaging/products, little consistent imagery with e-cigs
Those resembling traditional cigarettes associated with older smokers who want to quit – reinforced by POS
Some positive imagery from packaging of SKYCIG and VYPE, nightclubs, fashion, young males, discreet
Pink ‘shisha’ pen associated with positive imagery for some of the girls
“Cos it’s not like actually smoking, it’s more attractive”
“The doctor recommended ones, the boring ones” (boy, 11-12,)
“Does it come out pink smoke?”
“cool”
24. Next steps
Continuing to follow studies with young people that report on e-cigarette use in any country
Work with others on age of sale introduction and enforcement (good examples already exist)
Making the case for well designed studies that will help us understand how these products are perceived and used by youth
YTPS will report next Spring
Future longitudinal addition to YTPS
25. Thank you
Linda.Bauld@stir.ac.uk
Linda.Bauld@cancer.org.uk
Acknowledgements:
Kathryn Angus, Maciej Goniewicz,
Deborah Arnott, Allison Ford
& Anne-Marie Mackintosh